Storia in 1 fonti

Travere pays Everest $112M upfront to grow rare kidney disease pipeline

Travere Therapeutics pays $112 million upfront to Everest Medicines for ex-China rights to BTK inhibitor civorebrutinib, targeting rare kidney diseases.

Raccontata da

endpoints.news

Timeline cronologica

martedì 2 giugno 2026·endpoints.news
Travere pays Everest $112M upfront to grow rare kidney disease pipeline
Travere Therapeutics pays $112 million upfront to Everest Medicines for ex-China rights to BTK inhibitor civorebrutinib, targeting rare kidney diseases.